Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
|Condition or Disease||Intervention/Treatment||Phase|
||Early Phase 1|
Determine how fluorine F 18 clofarabine (18F-clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases.
Determine whether 18F-clofarabine can be used to image patients with autoimmune and inflammatory diseases.
Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.
Arms and Interventions
|Experimental: Imaging (fluorine F 18 clofarabine, PET/CT)
Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
Procedure: Computed Tomography
Undergo PET/CT scan
Radiation: Fluorine F 18 Clofarabine
Procedure: Positron Emission Tomography
Undergo PET/CT scan
Primary Outcome Measures
- Standardized Uptake Value [Baseline up to 240 minutes after injection]
Standardized Uptake Value (SUV) will be the primary unit for assessment. Using standard PET/CT viewing software, the SUV will be measured for different organs and lesions of suspected disease and compared to reference/background tissues.
Must be 18 years or older.
Diagnosed with an autoimmune and inflammatory disorder.
Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge.
Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical conditions including claustrophobia.
Contacts and Locations
|1||UCLA / Jonsson Comprehensive Cancer Center||Los Angeles||California||United States||90095|
Sponsors and Collaborators
- Jonsson Comprehensive Cancer Center
- Principal Investigator: Martin Allen-Auerbach, UCLA / Jonsson Comprehensive Cancer Center
Study Documents (Full-Text)None provided.